“We’re seeing a real shift in how NAD biology and the disease-modified NAD/B3 states are being understood and applied, and that’s opening up opportunities well beyond where the field was just a few years ago,” said Professor Anu Suomalainen Wartiovaara, co-founder and Chair of the Executive Board at NADMED, whose scientific research is the basis of NADMED. “Now the focus is on making what we’ve built more widely used internationally. James has worked at that kind of scale before, and he knows what it takes to turn strong science into something that reaches the people who can actually use it.”

James Lee

He has held commercial and operational leadership roles across multinational pharmaceutical and biotechnology companies, including Novo Nordisk, where he contributed to shaping the global launch strategy for Ozempic. Most recently, he served as Chief Brand Officer at Pharmanovia, where he was responsible for the company’s specialty medicines portfolio.

“NADMED’s technology addresses a fundamental biological system that is becoming increasingly important across research, diagnostics, and personalised health,” said Lee. “What stands out is how quickly the company has translated strong science into real commercial traction, with a presence in more than 30 countries. I see a clear opportunity to build on this foundation and scale its impact globally for researchers, clinicians, and patients.”

Jari Närhi is retiring

Current CEO Jari Närhi is retiring and, therefore, will step down from the CEO role at the company. Närhi, who co-founded NADMED Ltd and has led its development since inception, has played a central role in establishing the company’s foundation and early commercial traction. Närhi will remain available in an advisory capacity to support continuity during the transition period.